🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Immunoglobulin Light Chain (AL) Amyloidosis

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis NCT06022939Phase 3117 sites📍 Goodyear📍 Tucson📍 Tucson SWOG Cancer Research Network · Tests: Autologous Hematopoietic Stem Cell Transplantation, Biopsy, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow… Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research NCT07085559EARLY Phase 11 site📍 Hefei Anhui Provincial Hospital · Tests: Metabolically Armed BCMA CAR-T cells. Teclistamab in Previously Treated AL Amyloidosis NCT06935162Phase 21 site📍 Beijing Peking Union Medical College Hospital · Tests: Teclistamab (Tec) Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis NCT06699394NA2 sites📍 Beijing📍 Beijing Peking University People's Hospital · Tests: Teclistamab (Tec) A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL). NCT07638683Phase 21 site📍 Shanghai Shanghai Zhongshan Hospital · Tests: Teclistamab Investigating the Pathogenic Role of N-glycosylation in AL Amyloidosis: Molecular Bases, Diagnosis, and Treatment NCT07448779n/a1 site📍 Pavia Fondazione IRCCS Policlinico San Matteo di Pavia Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial NCT05898646Phase 22 sites📍 Scottsdale📍 Rochester Mayo Clinic · Tests: Bone Marrow Aspiration, Daratumumab, Echocardiography Test, Questionnaire Administration, X-Ray Imaging A EUropean REgistry and Sample Sharing networK to Promote the Diagnosis and Management of Light Chain Amyloidosis (EUREKA) NCT06205953n/a6 sites📍 Heidelberg📍 Pavia📍 Utrecht Fondazione IRCCS Policlinico San Matteo di Pavia Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource NCT01408225n/a1 site📍 Columbus Ohio State University Comprehensive Cancer Center · Tests: tissue banking SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell Disorders NCT07850284n/a1 site📍 Rochester Mayo Clinic · Tests: Non-Interventional Study Rapid dFLC Response Predict CHR in AL Amyloidosis NCT06627309n/a8 sites📍 Beijing📍 Beijing📍 Beijing Peking University People's Hospital · Tests: Dara IV, Bortezomib (drug), Dexamethasone, Cyclophosphamide (CTX), Dara SC BE.Amycon Biobank & Data Registry UZ Leuven NCT07172243n/a2 sites📍 Leuven📍 Leuven Universitaire Ziekenhuizen KU Leuven Daratumumab for Patients With Light Chain Amyloidosis NCT06376214NA1 site📍 Nanjing Nanjing University School of Medicine · Tests: Dratumumab / Hyaluronidase Injection [Darzalex Faspro], Pomalidomide 4 MG, autologous stem cell transplantation (ASCT) Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis NCT07079423Phase 21 site📍 Beijing Peking Union Medical College Hospital · Tests: Teclistamab (Tec) Optimize First-line Treatment for AL Amyloidosis With t (11; 14) NCT06192979NA7 sites📍 Beijing📍 Beijing📍 Beijing Jin Lu, MD · Tests: Daratumumab, Bortezomib, Dexamethasone, Venetoclax Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis NCT07250269Phase 19 sites📍 Beijing📍 Beijing📍 Beijing Gracell Biotechnologies (Shanghai) Co., Ltd. · Tests: GC012F Injection Clinical Study for AL-CM NCT04924998n/a1 site📍 Hangzhou Second Affiliated Hospital, Zhejiang University, School of … · Tests: current treatment of AL-CM One Gene, Two Diseases: the Pathologic Role of IGLV1-44 in AL Amyloidosis and POEMS NCT07448935n/a1 site📍 Pavia Fondazione IRCCS Policlinico San Matteo di Pavia A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis. NCT07081646Phase 1, Phase 218 sites📍 Phoenix📍 San Francisco📍 Tampa Alexion Pharmaceuticals, Inc. · Tests: AZD0120 A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion NCT06158854Phase 1, Phase 223 sites📍 Miami📍 Boston📍 Rochester AbbVie · Tests: ABBV-383 (Etentamig) Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis NCT06569147Phase 1, Phase 25 sites📍 New Haven📍 Boston📍 Boston Dana-Farber Cancer Institute · Tests: Elranatamab Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis NCT05145816Phase 1, Phase 23 sites📍 Nashville📍 Dallas📍 Salt Lake City University of Texas Southwestern Medical Center · Tests: Belantamab mafodotin 2.5 mg/kg (8 weeks), Belantamab mafodotin 1.9 mg/kg (8 weeks), Belantamab mafodotin 1.4 mg/kg (12 … International Cardiac Amyloidosis Registry NCT06894290n/a6 sites📍 Bruges📍 Edegem📍 Roma Leiden University Medical Center Promoting Diagnosis and Management of AL in Italy (ProDigALIty) NCT06383143n/a4 sites📍 Bari📍 Catania📍 Pavia Fondazione IRCCS Policlinico San Matteo di Pavia · Tests: no intervention A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma NCT06768489Phase 116 sites📍 Denver📍 Atlanta📍 Clayton Janssen Research & Development, LLC · Tests: JNJ-79635322, Daratumumab, Pomalidomide, Lenalidomide A Registry of AL Amyloidosis (ReAL) NCT04839003n/a1 site📍 Pavia Fondazione IRCCS Policlinico San Matteo di Pavia A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis NCT05951816Phase 11 site📍 Knoxville University of Tennessee Graduate School of Medicine · Tests: 99mTc-p5+14 is an amyloid reactive peptide labeled with technetium-99m., 99mTc-Pyrophosphate National Registry of Rare Kidney Diseases NCT06065852n/a1 site📍 Bristol UK Kidney Association Evaluation of Skin Tests in Biotherapy Allergies NCT06971848NA1 site📍 Angers University Hospital, Angers · Tests: Drug skin tests (investigating hypersensitivity to a biotherapy) A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis NCT07224672Phase 25 sites📍 Rochester📍 Westmead📍 Woolloongabba GlaxoSmithKline · Tests: Belantamab mafodotin, Cyclophosphamide, Bortezomib, Dexamethasone
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy